Department of Pharmacology, University College of Medical Sciences (University of Delhi) and Guru Teg Bahadur Hospital, New Delhi, India.
Department of Biochemistry, University College of Medical Sciences (University of Delhi) and Guru Teg Bahadur Hospital, New Delhi, India.
Int J Psychiatry Clin Pract. 2024 Mar;28(1):9-16. doi: 10.1080/13651501.2023.2287754. Epub 2023 Nov 29.
This study evaluated the effect of sertraline with desvenlafaxine and sertraline with mirtazapine on HAM-D score and inflammatory markers (IL-6 and TNF-α levels) in major depressive disorder.
Patients (18-60 years) with MDD diagnosed by DSM-V criteria and HAM-D score 18 or more were included ( = 60). Group A patients ( = 30) received sertraline 50 mg/day and desvenlafaxine 50 mg/day. Group B patients ( = 30) received sertraline 50 mg/day and mirtazapine 30 mg/day. All patients were followed up for 8 weeks for the evaluation of clinical efficacy, safety, serum IL-6, and TNF-α levels.
Our study showed a comparatively similar and statistically significant ( < 0.05) reduction in HAM-D score in both groups in the 4th and 8th week of the treatment. Both drug combinations significantly ( < 0.05) decreased serum IL-6 and TNF-α after 8 weeks of treatment.
The present study suggests that the combination therapy (as treatment initiation) with sertraline and desvenlafaxine, and sertraline with mirtazapine is effective and well tolerated in MDD patients with moderate to severe depression, and their therapeutic efficacy is accompanied by decreased inflammatory markers (serum IL-6 and TNF-α).
本研究评估了舍曲林与去甲文拉法辛和舍曲林与米氮平联用对重度抑郁症患者汉密尔顿抑郁量表（HAM-D）评分和炎症标志物（IL-6 和 TNF-α 水平）的影响。
符合 DSM-V 诊断标准且 HAM-D 评分≥18 分的抑郁症患者（年龄 18-60 岁）纳入研究（n=60）。A 组患者（n=30）给予舍曲林 50mg/日和去甲文拉法辛 50mg/日；B 组患者（n=30）给予舍曲林 50mg/日和米氮平 30mg/日。所有患者均接受 8 周随访，评估临床疗效、安全性及血清 IL-6 和 TNF-α 水平。
本研究显示，两组患者在治疗第 4 周和第 8 周 HAM-D 评分均有显著下降（P＜0.05），且具有可比性。两种药物联合治疗 8 周后均可显著降低血清 IL-6 和 TNF-α（P＜0.05）。
本研究表明，舍曲林与去甲文拉法辛和舍曲林与米氮平的联合治疗（起始治疗）对中重度抑郁症患者有效且耐受性良好，其疗效可伴随炎症标志物（血清 IL-6 和 TNF-α）的降低。
